Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CBUS
CBUS logo

CBUS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cibus Inc (CBUS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.360
1 Day change
5.43%
52 Week Range
4.190
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Cibus Inc (CBUS) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite a recent price increase and potential catalysts in the EU regulatory environment, the lack of strong financial data, bearish moving averages, and neutral trading sentiment suggest that this stock does not currently present a compelling long-term investment opportunity. A 'hold' position is recommended until more positive financial or market developments occur.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 63.446, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 1.374 and 1.43, while support levels are at 1.19 and 1.134.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
5

Positive Catalysts

  • The company has cash runway through 3Q26.

Neutral/Negative Catalysts

  • No recent news, no significant insider or hedge fund trading trends, and no recent congress trading data. The stock has bearish moving averages and lacks strong financial performance data.

Financial Performance

No financial data available for analysis. Latest quarter season information is missing.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Jefferies maintains a Hold rating but raised the price target to $3 from $1.90, citing cost-cutting measures and a capital raise that provide cash runway through 3Q26.

Wall Street analysts forecast CBUS stock price to rise
3 Analyst Rating
Wall Street analysts forecast CBUS stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.290
sliders
Low
15
Averages
18.67
High
25
Current: 1.290
sliders
Low
15
Averages
18.67
High
25
Jefferies
Hold
maintain
$3
AI Analysis
2026-03-25
Reason
Jefferies
Price Target
$3
AI Analysis
2026-03-25
maintain
Hold
Reason
Jefferies raised the firm's price target on Cibus to $3 from $1.90 and keeps a Hold rating on the shares. With the capital raise in January and cost cutting measures, Cibus aims tot have ample cash for operating expenses and capex through at least 3Q26, the analyst tells investors in a research note. With EU genetic engineering regulations likely finalized in Q2, the firm expects a pickup in customer engagement in trait insertion, single-cell cloning, field trial efficiency solutions, and biofragrance production.

People Also Watch